1. -  Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors

    -  Study to start enrollment in the third quarter of 2021 in Australia, with expansion to additional sites in the US, UK and Canada

    -  Presentation by management team to take place today, July 27, 2021, at 2:00 p.m. ET

    TORONTO and HOUSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, is providing an update on its MDNA11 program today. The update will be delivered by Dr. Fahar Merchant, President and CEO of Medicenna, together with Dr. Mann Muhsin (Chief Medical Officer) and Ms. Elizabeth…

    View Full Article
  2. -- Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression, improved survival, and long-term immune memory effect

    -- The data highlight the ability of MDNA109 armed oncolytic virus to reshape the tumor microenvironment from an immunosuppressive to a pro-inflammatory one and its potential to treat immunologically "cold" tumors such as pancreatic cancer

    TORONTO and HOUSTON, July 14, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced the peer-reviewed publication of preclinical data on MDNA109…

    View Full Article
  3. -- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021

    -- Trial is designed to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors

    -- Preliminary update on safety, PK/PD, and biomarker data expected by year end

    TORONTO and HOUSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it has submitted a clinical trial application to a Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1/2 clinical study of MDNA11, the Company's selective, long-acting and novel…

    View Full Article
  4. -- Management hosting conference call and webcast today at 8:30 AM ET

    TORONTO and HOUSTON, May 28, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

    "The strong momentum we have generated over the past year leaves us poised to achieve key milestones that will lay a solid foundation for expansion of our clinical-stage pipeline," said Fahar Merchant, PhD, President and CEO of Medicenna. "We have recently added significant talent, expertise…

    View Full Article
  5. TORONTO and HOUSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on May 28, 2021 at 8:30 AM ET to report its financial results for the fiscal year ended March 31, 2021 and operational highlights.

    To access the call, please dial (877) 407-9716 from Canada or the United States or (201) 493-6779 internationally, followed by the conference ID: 13719231. To access the live webcast, please go to the investors section of Medicenna's website at https://ir.medicenna.com/news-and-events/events-and-presentations. Following the live webcast, an archived version of the…

    View Full Article